Innovare R&D was founded in 1995 with the scope of a CMO in the field of generic products, mostly synthetic hormones. Despite the fact that the generic unit is ongoing, at a smaller size, since 2008 through a completely new Board of Directors and shareholders, the Company´s focus of business has been driven into novel, high specialty products in the Hematology, Immunology, and Infectious Disease fields.
Contact details
Innovare R&D
Paseo de la Reforma 2620 PH 4
Col. Lomas Altas
CP 11950, México DF
MEXICO
Tel: +52 (55) 5273 6055
Website: http://www.innovare-rd.com.mx/
Gerardo Cárdenas Vogel, CEO of Innovare R&D, on transforming the company’s business model to benefit from drug development opportunities, Mexico as a world-class clinical trial destination, and new, innovative treatments…
In Mexico, more than 13 million people live with diabetes, while 71 percent of the total population have obesity or are overweight. Morten Vaupel, vice-president and general manager of Novo…
Raul Vivar, recently appointed GM of Eisai Mexico, describes the main achievements of the Japanese company in Mexico, the challenges that innovative companies face entering the Mexican market, and the…
Raúl Riquelme Cacho, president of the health commission of the Confederation of Industrial Chambers of the United Mexican States (CONCAMIN), reveals the recent alignment of CONCAMIN, which stands as the…
Efrén Ocampo, CEO of the Mexican pharmaceutical group Neolpharma, details the strategic thinking that has fostered the emergence of one of the most prominent healthcare groups in Mexico and the…
Hetero, the global API leader, has consolidated its position as the partner of choice of the pharmaceutical industry in Mexico, with a portfolio of more than 300 APIs. GM Gurulinga…
Fernando Oliveros, VP of Medtronic Mexico, explains how the global medical devices leader wants to leverage Covidien’s integration to improve health outcomes in Mexico. By taking advantage of an innovative…
Lundbeck Mexico GM Oscar Parra discusses raising awareness of depression in Mexico, Lundbeck’s innovative treatments for depression and Alzheimer’s, and managing to navigate the country’s regulatory process to ultimately benefit…
Daniel Pardo Bejarano, CEO of BOMI Mexico, details the competitive advantages and the unique business approach that make BOMI the logistics partner of choice of the Mexican healthcare industry, while…
In light of the recently released OECD Reviews of Health Systems: Mexico 2016, Roberto Martinez, general director of the OECD Mexico Center for Latin America, reveals the OECD’s key findings…
Gabriel O’Shea, National Commissioner of Seguro Popular, on how the institute generates more efficient and transparent resource allocation across Mexico as the country prepares to implement medical service exchange among…
Francisco González, CEO of ProMéxico, the Mexican investment agency, describes the strengths of Mexico’s research and industrial base, untapped business opportunities in the pharmaceutical and healthcare sectors, and new export…
See our Cookie Privacy Policy Here
